



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology

Andersen, Vibeke; Svenningsen, Katrine; Knudsen, Lina Almind; Hansen, Axel Kornerup; Holmskov, Uffe; Stensballe, Allan; Vogel, Ulla

Published in:
World Journal of Gastroenterology

DOI (link to publication from Publisher):
[10.3748/wjg.v21.i41.11862](https://doi.org/10.3748/wjg.v21.i41.11862)

Publication date:
2015

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Andersen, V., Svenningsen, K., Knudsen, L. A., Hansen, A. K., Holmskov, U., Stensballe, A., & Vogel, U. (2015). Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. *World Journal of Gastroenterology*, 21(41), 11862-11876. DOI: 10.3748/wjg.v21.i41.11862

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- ? You may not further distribute the material or use it for any profit-making activity or commercial gain
- ? You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Novel understanding of ABC transporters ABCB1/MDR/ P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology

Vibeke Andersen, Katrine Svenningsen, Lina Almind Knudsen, Axel Kornerup Hansen, Uffe Holmskov, Allan Stensballe, Ulla Vogel

Vibeke Andersen, Katrine Svenningsen, Lina Almind Knudsen, Molecular Diagnostic and Clinical Health Research Unit, Hospital of Southern Jutland, 6200 Aabenraa, Denmark

Vibeke Andersen, Katrine Svenningsen, Lina Almind Knudsen, Institute of Regional Health Research-Centre Sønderjylland, University of Southern Denmark, 5000 Odense, Denmark

Vibeke Andersen, Medical Department, Regional Hospital Viborg, 8800 Viborg, Denmark

Axel Kornerup Hansen, Experimental Animal Models, University of Copenhagen, 1870 Frederiksberg, Denmark

Uffe Holmskov, Department of Cancer and Inflammation Research, University of Southern Denmark, 5000 Odense, Denmark

Allan Stensballe, Department of Health Science and Technology, Aalborg University, 9220 Aalborg, Denmark

Ulla Vogel, National Research Centre for the Working Environment, 2100 Copenhagen, Denmark

Author contributions: Andersen V was the guarantor of the article, collected the material and wrote the manuscript; Vogel U critically commented the work; Svenningsen K, Knudsen LA, Hansen AK, Holmskov U, Stensballe A and Vogel U participated in the manuscript writing; all authors have accepted the final version.

Conflict-of-interest statement: Vibeke Andersen is receiving compensation as a consultant for MSD (Merck) and Janssen and advisory board member for MSD (Merck). Katrine Svenningsen, Lina A Knudsen, Axel Kornerup Hansen, Uffe Holmskov, Allan Stensballe, and Ulla Vogel declare no competing interests.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this

work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: Dr. Vibeke Andersen, Molecular Diagnostic and Clinical Health Research Unit, Hospital of Southern Jutland, 6200 Aabenraa, Denmark. vandersen@health.sdu.dk
Telephone: +45-21157790
Fax: +45-88834488

Received: June 10, 2015
Peer-review started: June 14, 2015
First decision: July 14, 2015
Revised: August 7, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: November 7, 2015

Abstract

AIM: To evaluate ATP-binding cassette (ABC) transporters in colonic pathophysiology as they had recently been related to colorectal cancer (CRC) development.

METHODS: Literature search was conducted on PubMed using combinations of the following terms: ABC transporters, ATP binding cassette transporter proteins, inflammatory bowel disease, ulcerative colitis, Crohns disease, colorectal cancer, colitis, intestinal inflammation, intestinal carcinogenesis, ABCB1/P-glycoprotein (P-gp/CD243/MDR1), ABCC2/multidrug resistance protein 2 (MRP2) and ABCG2/breast cancer resistance protein (BCRP), *Abcb1/Mdr1a*, *abcc2/Mrp2*, *abcg2/Bcrp*, knock-out mice, tight junction, membrane lipid function.

RESULTS: Recently, human studies reported that

changes in the levels of ABC transporters were early events in the adenoma-carcinoma sequence leading to CRC. A link between ABCB1, high fat diet and gut microbes in relation to colitis was suggested by the animal studies. The finding that colitis was preceded by altered gut bacterial composition suggests that deletion of *Abcb1* leads to fundamental changes of host-microbiota interaction. Also, high fat diet increases the frequency and severity of colitis in specific pathogen-free *Abcb1* KO mice. The *Abcb1* KO mice might thus serve as a model in which diet/environmental factors and microbes may be controlled and investigated in relation to intestinal inflammation. Potential molecular mechanisms include defective transport of inflammatory mediators and/or phospholipid translocation from one side to the other of the cell membrane lipid bilayer by ABC transporters affecting inflammatory response and/or function of tight junctions, phagocytosis and vesicle trafficking. Also, diet and microbes give rise to molecules which are potential substrates for the ABC transporters and which may additionally affect ABC transporter function through nuclear receptors and transcriptional regulation. Another critical role of ABCB1 was suggested by the finding that ABCB1 expression identifies a subpopulation of pro-inflammatory Th17 cells which were resistant to treatment with glucocorticoids. The evidence for the involvement of ABCC2 and ABCG2 in colonic pathophysiology was weak.

CONCLUSION: ABCB1, diet, and gut microbes mutually interact in colonic inflammation, a well-known risk factor for CRC. Further insight may be translated into preventive and treatment strategies.

Key words: ATP-binding cassette transporters; Colorectal cancer; Intestinal; Inflammatory bowel disease; Inflammation; Adenoma-carcinoma sequence

© **The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Recently, human studies reported that changes in the levels of ATP-binding cassette (ABC) transporters were early events in the adenoma-carcinoma sequence leading to colorectal cancer. A link between ABCB1, high fat diet and gut microbes in relation to colitis was suggested by the animal studies. The *Abcb1* KO mice might thus serve as a model in which diet/environmental factors and microbes may be controlled and investigated in relation to intestinal inflammation. Such strategy may provide insight which can be translated into preventive and treatment strategies to benefit the patients.

Andersen V, Svenningsen K, Knudsen LA, Hansen AK, Holmskov U, Stensballe A, Vogel U. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. *World J Gastroenterol* 2015; 21(41): 11862-11876 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v21/i41/11862.htm> DOI:

INTRODUCTION

Colorectal cancer (CRC) constitutes the third most common cancer in the world and the second leading cause of cancer-related deaths. The number of cases is increasing and has been estimated to raise from 1.4 million cases in 2012 to 2.4 million cases in 2035 worldwide^[1]. Early detection of CRC is important as early treatment has been associated with improved outcomes and saved lives^[2]. Therefore, population screening programs have been initiated in a number of countries such as the United Kingdom, Australia, Holland and Denmark^[3-6]. The fecal occult blood test (FOBT) is the most widely used for population screening^[7] and individuals with a positive FOBT are referred for an endoscopic investigation of the colonic mucosa thereby enabling the sampling of biopsies from the colonic mucosa.

Recently, a major part of research had focused on improving prognosis and treatment selection in CRC^[8-10]. Another approach could be to prevent the development of cancer in subgroups of patients with high risk, *i.e.*, secondary prevention. Thus, the molecular evaluation of the (unaffected) colonic mucosa from the patients undergoing an endoscopic evaluation could potentially stratify the patients according to their risk of developing CRC. Our recent findings indicate that even healthy looking mucosa as determined by histology may contain a significantly elevated level of immune response proteins^[11]. Biomarkers potentially predicting the disease risk among selected patient groups could improve the efficiency of the screening programs and patient care. Furthermore, they have the potential to dramatically alter the established patient care pathways as follow-up of the patients may be tailored according to their individual risk and thereby the organization and use of resources of the health care system.

CRC develops in the colonic mucosa which is highly affected by the metabolic activities in the intestinal lumen. The dietary items reaching the colon are digested by the commensal bacteria giving rise to various substrates which may prevent, initiate or promote colorectal cancer development^[12]. Thus, in order to understand the processes leading to CRC we need to take into account the delicate interactions between dietary intake, activity of the commensal bacteria and host factors.

We recently reported that low *ABCB1* and *ABCG2* gene transcription levels and high *ABCC2* levels are early events in the colorectal adenoma-carcinoma sequence^[13,14] suggesting that changes in expression levels of the ATP binding cassette (ABC) transporter proteins [EC 3.6.3.44] precede cancer development. In addition, inflammatory bowel disease (IBD) may be

a risk factor for the development of CRC^[8]. Therefore, we wanted to discuss the current understanding of how these ABC transporters may affect intestinal inflammation and carcinogenesis, how they may potentially interact with the environment such as diet and gut microbes, and whether this knowledge may be utilized for improved treatment care strategies.

MATERIALS AND METHODS

Literature search was conducted on PubMed using combinations of the following terms: ABC transporters, ATP binding cassette transporter proteins, inflammatory bowel disease, ulcerative, colitis, Crohn's disease, colorectal cancer, colitis, intestinal inflammation, intestinal carcinogenesis, ABCB1/P-glycoprotein (P-gp/CD243/MDR1), ABCC2/multidrug resistance protein 2 (MRP2) and ABCG2/breast cancer resistance protein (BCRP), *Abcb1/Mdr1a*, *abcc2/Mrp2*, *abcg2/Bcrp*, knock-out mice, tight junction, membrane lipid function.

RESULTS

ABC family of transporters; ABCB1, ABCC2, and ABCG2

The large family of ABC transporter proteins is highly conserved through evolution and extensive sequence and protein homology is shared between numerous bacterial and eukaryotic ABC transport proteins^[15]. The ABC proteins are found in the cell membranes and intracellular organelles and the ABC family members exert multiple different functions depending on the cellular context^[16].

The ABCB1, ABCC2, and ABCG2 transporters, encoded by *ABCB1*, *ABCC2*, and *ABCG2*, respectively, are located in the apical cell membrane of epithelial and endothelial interfaces within the intestine, testis, kidneys, liver, brain, and placenta^[17-20]. Thereby, they exert barrier functions influencing absorption, distribution, excretion, and toxicology (ADME-Tox) of exogenous substrates with potential impact on inflammation and carcinogenesis^[21-25]. ABCB1 and ABCG2 transporters have also been identified on haematological cells^[20,26,27]. Whereas ABCB1 has been extensively studied in relation to the gastrointestinal system^[28], less is known for ABCC2 and ABCG2^[29].

No monogenic diseases have been identified involving *ABCB1* and *ABCG2*^[30,31], but several different mutations in *ABCC2* have been observed in patients with Dubin-Johnson syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia^[32].

Nuclear receptors such as aryl hydrocarbon receptor (AHR), pregnane x receptor (PXR, NR1I2), vitamin D receptor (VDR, NR1I1), and constitutive androstane/activated receptor (NR1I3) are activated by a wide variety of exogenous and endogenous factors including diet, heavy metals, gut microbes, carcinogens and inflammation^[33,34] (reviewed in^[35]). These nuclear

receptors may be involved in the transcriptional regulation of ABC transporters^[34,36-40] as are the transcription factors nuclear factor kappa B (NF- κ B), activator protein 1 (AP-1)^[41], and Wnt signaling transcription factor TCF4^[42]. Furthermore, ABCB1 undergoes several posttranslational modifications (PTMs)^[43,44] which have been shown to affect the stability of ABCB1 and/or substrate transport specificities^[45]. ABCB1 is a 170-180 kDa glycoprotein with N-linked glycosylation at residues Asp⁹¹, Asp⁹⁴ and Asp⁹⁹. ABCB1 and ABCC2 have two ATP-binding sites and two six-transmembrane domains in a symmetric structure whereas ABCG2 is a half-transporter and have one ATP binding site and one six-transmembrane domain.

ABC transporter substrates include many diverse endogenous and exogenous molecules including amino acids, peptides, metabolites, vitamins, fatty acids, steroids, phospholipids, conjugated organic anions, and dietary and environmental carcinogens, pesticides, metals, metalloids, lipid peroxidation products and drugs^[22-24]. Substrate overlap has been reported between the ABCB1, ABCC2, ABCG2, and especially between ABCC2 and the basolaterally located ABCC1^[23,29]. Specific substrates and their potential role in ABC transporter related gut inflammation will be discussed later in this review.

Inflammation is a key factor underlying the development of CRC

CRC is a heterogeneous disease complex with environmental, genetic and host factors involved in the aetiology^[46,47]. Inflammation is a risk factor for CRC^[48-50] and accordingly, a subset of patients with IBD^[51,52] [with the two main forms ulcerative colitis (UC) and Crohn's disease (CD)] characterised by long-term and extensive colitis are at high risk of CRC^[53,54]. The incidences of both CRC and IBD are rising^[1,55], which point to important roles of environment factors.

The intestinal mucosa is by far the body's largest surface exposed to and interacting with environmental factors. The intestinal epithelium and the mucus form a barrier against luminal antigens and invading microbes^[56,57]. Microbial sensing by intestinal epithelium cells and local innate lymphoid cells (ILCs) through pattern recognition receptors (PRR) leads to secretion of pro-inflammatory cytokines such as tumour necrosis factor- α (TNF- α), interferon- γ (INF- γ), interleukin 6 (IL-6), and IL-17^[58,59], cytokines which have been related to IBD and CRC^[60]. Activation of PRR stimulates autophagocytic networks^[61,62]. Also, activation of the innate immune system may result in activation of the adaptive immune response with T cell involvement; Th1, Th2 and Th17 cells characterised by secretion of their signature cytokines INF- γ , IL-4, IL-17, respectively, whereas Tregs (and to a lesser degree Th2), in contrast, are characterised by their production of the anti-inflammatory cytokines IL-10 and transforming growth factor β (TGF- β)^[63,64]. The

Table 1 The *ABCB1*, *ABCC2* and *ABCG2* mRNA and protein levels in intestinal tissue from patients with ulcerative colitis

		Controls		Inactive disease		Active disease				Ref.
		Colon	Rectum	Colon	P value	Rectum	P value	Colon	P value	
Gene	<i>ABCB1</i> ¹	1 (ref)	NA	NS	NA	22%	< 0.001	34%	< 0.01	[72]
	<i>ABCC2</i> ¹	1 (ref)	NA	NS	NA	NA	NS	NA	NS	[72]
	<i>ABCG2</i> ¹	1 (ref)	NA	NS	NA	11%	< 0.001	16%	< 0.001	[72]
Array	<i>ABCB1</i> ²	287	-1.5							[40]
	<i>ABCC2</i> ²	81	-8.6							[40]
Protein	<i>ABCG2</i> ³	100 (9/9)	80 (53/67)			24 (13/54)	0.01			[73]

¹The *ABCB1*, *ABCC2* and *ABCG2* mRNA levels in colon and rectum tissue from patients with ulcerative colitis in remission ($n = 17$) or with active disease ($n = 16$) compared to the levels in colon tissue from healthy controls ($n = 17$). mRNA levels are normalised to the villin mRNA level. *P* values compared to the expression in the controls; ²Microarray analyses of pooled cRNA from uninflamed colonic tissue from 4 patients with UC and 4 control subjects. Fold change expression in colon tissue compared to controls. Statistically significant expression levels of *ABCB1* were found in UC patients compared to controls by RT-PCR analyses using 18S RNA as internal control ($P < 0.05$); ³Quantitative immunohistochemistry of formalin-fixed paraffin-embedded (FFPE) colonic biopsies from 9 healthy individuals and 36 patients with ulcerative colitis. The values are n % (samples with positive staining/total number). *P* value for active colitis compared to controls and inactive colitis, respectively. NA: Not available; NS: Not significant.

role of the Th17-associated cytokines in animal models of colitis^[65], IBD^[66] and CRC^[67] have been in focus the recent years and it has been suggested that Th17 cells may have evolved to combat bacterial and fungal infections *via* orchestration of the neutrophil inflammatory response^[63]. However, this seems to be a simplistic view^[68] and more T cell subsets with as yet unclarified functions in IBD and CRC have been identified these years^[69-71].

ABC transporters, IBD and CRC

Englund *et al.*^[72] found significantly lower levels of both *ABCB1* and *ABCG2* mRNA in colon and rectal biopsies from 16 patients with active UC compared to healthy individuals whereas the levels did not differ between UC patients in remission and healthy controls (Table 1). The authors also reported lower *ABCB1* and *ABCG2* levels in colon from patients with active inflammation compared with controls^[72]. Langmann *et al.*^[40] reported low levels of *ABCB1* and *ABCC2* mRNA in biopsies from colon adjacent to inflammation from patients with UC compared to the levels in controls. In contrast, Deuring *et al.*^[73] reported similar levels of *ABCG2* mRNA in intestinal biopsies from healthy individuals, patients in remission and patients with active inflammation but dramatically reduced levels of *ABCG2* in IBD patients with active inflammation when compared to patients in remission or healthy controls using quantitative immunohistochemistry (Table 1). These observations suggest that the low levels of *ABCG2* observed in inflamed colon were caused by posttranscriptional processes^[73]. The study also found inflamed colon to contain high levels of the endoplasmic reticulum (ER)-stress marker GRP78 and *in vitro* they found nitric oxide induced ER-stress to impair *ABCG2* function^[73]. The authors therefore suggested that incorrect protein folding caused by inflammation-induced ER dysfunction may lead to low levels of *ABCG2* in inflamed colon of IBD patients^[73,74].

The role of ABC transporters has also been investigated in relation to CRC (Table 2). As previously

mentioned, low levels of *ABCB1* in colon was found to be an early event that preceded malignancy^[13]. Similarly, in another study using the same cohort low levels of *ABCG2* and high levels of *ABCC2* mRNA were found in both colon adenomas and carcinomas compared to morphological normal tissue surrounding the cancer tissue, and compared to levels in tissue from healthy individuals^[14]. Taken together, the studies suggest that changed expression levels of the ABC transport proteins may be early events in the development of IBD and CRC.

Genetically determined variation in ABC transporters has been investigated in relation to risk of developing IBD^[75-79] and CRC^[80-82] with varying results^[83-85]. In particular the polymorphisms *ABCB1* C1236T, G2677T/A, and C3435T have been investigated. These polymorphisms are in linkage disequilibrium. Haplotype frequencies vary among ethnic groups and the CGC and TTT haplotypes are frequent among Caucasians^[86]. The synonymous C3435T polymorphism was reported to cause changes in protein folding due to ribosome stalling caused by impaired interaction between the tRNA and the chaperone protein that aids the folding process at the ribosome^[86] which resulted in altered transporter function^[87]. A recent meta-analysis found that the *ABCB1* C3435T polymorphism (rs1045642) was associated with risk of UC, but not with CD^[84]. In relation to CRC, a large case-control analysis of a Czech and two German cohorts of 4677 cases in total found no indications of a strong role of *ABCB1* in CRC^[88] which was in accordance with a meta-analysis (not including the above study)^[85]. A prospective study based on a Danish cohort found that two *ABCB1* polymorphisms, including the C3435T polymorphism, were associated with CRC risk^[82]. Furthermore, these two polymorphisms were found to interact with meat intake in relation to risk of CRC. Only few studies of *ABCC2* and *ABCG2* polymorphisms as risk factors for IBD and CRC have been performed. No strong indications that genetic variation in *ABCC2* or *ABCG2 per se* is associated with IBD or CRC were

Table 2 The *ABCB1*, *ABCC2* and *ABCG2* mRNA levels in intestinal tissue from patients with adenomas and colorectal cancer and healthy individuals

	Unaffected tissue	<i>P</i> value ¹	Adenomas/carcinomas	<i>P</i> value ¹	<i>P</i> value ²	Ref.
<i>ABCB1</i>						
Healthy individuals	0.012 ± 0.008					[13]
Mild/moderate dysplasia cases	0.009 ± 0.004	NS	0.005 ± 0.004	< 0.050	< 0.001	
Severe dysplasia cases	0.009 ± 0.030	NS	0.003 ± 0.002	< 0.050	< 0.001	
Cancer patients	0.009 ± 0.014 (distant)	< 0.05	0.003 ± 0.005	< 0.001	< 0.001	
	0.007 ± 0.009 (adjacent)	< 0.05			< 0.010	
<i>ABCC2</i>						
Healthy individuals	5.35 ± 3.24					[14]
Mild moderate dysplasia cases	4.62 ± 4.79	0.081	6.68 ± 6.77	0.87	0.037	
Severe dysplasia cases	6.66 ± 8.47	0.880	10.18 ± 11.52	0.27	0.240	
Cancer patients	28.06 ± 68.84 (distant)	0.036	87.50 ± 270.21	0.0046	0.0037	
	11.44 ± 25.58 (adjacent)	0.690			< 0.0001	
<i>ABCG2</i>						
Healthy individuals	718.06 ± 761.24					[14]
Mild moderate dysplasia	732.85 ± 2305.28	0.550	56.02 ± 118.42	< 0.0001	< 0.0001	
Severe dysplasia	448.02 ± 195.34	0.840	76.31 ± 102.63	< 0.0001	< 0.0001	
Cancer patients	6679 ± 58353 (distant)	0.080	98.41 ± 476.36	< 0.0001	< 0.0001	
	1302 ± 10090 (adjacent)	0.011			< 0.0001	

¹*P* values for comparison of the expression levels in tissue from healthy individuals adjusted for age and gender. Samples were available for 18 healthy controls, 88-94 patients with mild/moderate dysplasia, 12 with severe dysplasia, and 121-122 patients with CRC; ²*P* value for the comparison of the expression levels in morphologically unaffected and affected tissue from the same individual using Paired Student's *t*-test. All values are mean ± SD. *ABCB1* mRNA levels are normalised to the *β-actin* mRNA level. *ABCC2* and *ABCG2* mRNA levels are normalised to 18S RNA levels. Matching samples were available from *ABCC2*: 66-75 cases with mild-moderate dysplasia, 11 cases with severe dysplasia, and 63-80 and 66-99 CRC cases (distant unaffected tissue, and adjacent unaffected tissue, respectively). NS: Not significant.

found^[80,81].

ABC transporters and colitis and dysplasia in animal models

The *Abcb1/Mdr1a* knock-out (*Mdr1a* KO) mouse, in which the gene corresponding to the human intestinal *ABCB1* gene has been deleted^[89,90], has been utilized as an animal model of colitis^[91-95]. The colitis is characterized by histological changes and high levels of the cytokines INF- γ , TNF- α , IL-1 β , IL-6 and IL-17 thus resembling the findings in UC patients. The classical study by Panwala *et al.*^[91] reported that a proportion of *Mdr1a* KO mice developed colitis when exposed to commensal gut bacteria. The development of spontaneous colitis was prevented if the mice were maintained germfree. Also, spontaneous colitis and active inflammation was resolved by oral treatment with a mixture of streptomycin, neomycin, bacitracin, and amphotericin. These findings highlight an important role of bacteria in the initiation and perpetuation of colitis in the *Mdr1a* KO mouse^[91]. Since then, the finding that lack of *Mdr1a* confers risk of colitis has been replicated by others^[94-98]. Furthermore, a proportion of the *Mdr1a* KO mice dual-infected with *Helicobacter* species (*H. bilis* and *H. hepaticus*) developed dysplasia^[99].

One study found reduced diversity and total number of bacteria in *mdr1a* KO mice compared to wildtype mice. These alterations were found to precede and associate with the development of inflammation^[95]. Another study reported changes in colonic gene expression which also preceded disease

development^[98]. High expression of INF- γ was found in histologically normal colonic tissue from *Mdr1a* KO mice and the change preceded a high expression of the inflammatory cytokines IL-1 β , IL-6, TNF- α , increased colonic permeability, and histologically determined colon inflammation^[98]. Yet, another study found a high level of the pro-inflammatory cytokine IL-17 in colon from the *Mdr1a* KO mice model^[92]. INF- γ expression has been associated with reduced intestinal barrier function due to effects on tight junction proteins^[96]. Also, one study suggested that impaired intestinal barrier function contributed to the development of colitis in *Mdr1a* KO mice. In this study, high permeability of FITC-dextran (4.4 kDa) and horseradish peroxidase (44 kDa) was found in colon tissue mounted in Ussing chambers and *in vivo*, high bacterial translocation to lymphoid tissue including increased trabecular infiltrate with neutrophils were found^[94]. These changes were observed prior to onset of colitis. Furthermore, decreased phosphorylation of tight junction proteins including occludin was observed^[94]. Thus, inflammation and the following high INF- γ expression may contribute to the loss of barrier function which has been observed in the *Abcb1* KO mice.

High fat diet-induced obesity increases the frequency and severity of colitis in the *mdr1a* KO mice^[100]. Wildtype mice feeding either high-fat diet or low fat diet did not develop colitis^[100]. In contrast, specific pathogen free *Mdr1a* KO mice fed high fat diet had a higher frequency and more severe colitis compared to those who were fed a low fat diet^[100]. Although




Figure 1 The models presented are from Tarning *et al.*^[16]. A: Lipids can move across the membrane bilayer by multiple mechanisms. Four mechanisms are proposed here: (1) membrane lipids passively diffuse or "flip-flop" from one leaflet of the bilayer to another; (2) bi-directional movement of lipids from one membrane leaflet to another is enhanced by proteins present in the membrane bilayer; (3) P-type ATPases mediate the movement of specific lipids (phospholipids) from the outer leaflet of the membrane bilayer; and (4) ABC transporters/flippases mediate the "outward" movement of specific lipids (phospholipids/cholesterol) from the inner leaflet to the outer leaflet of the membrane bilayer; B: Mechanisms of substrate recognition and transport by ABC transport proteins: (1) substrates enter the transporter from the inner leaflet and are flipped to the outer leaflet where they can exit the membrane bilayer; (2) as in (1) but the substrate exits the transporter directly to an exogenous acceptor; (3) solute/ions/amphiphiles move directly into the bilayer, through the transporter protein and out to the external environment; and (4) substrates enter the transporter from the outer leaflet and exits to an acceptor molecule.

the microbiota was not investigated in this study, the authors concluded that the diet and potential diet-induced changes in microbiota was not sufficient to induce colitis in the mice but that additional host genetic factors are required before the high fat diet is a risk factor for colitis^[100].

Impaired immune system may also be involved in the aetiology of colitis in the *Mdr1a* KO mice model. In mice, regulatory T cells (Tregs) characterised by the expression of the transcription factor Foxp3^[101] are considered to down-regulate effector T cells that react to microbial or other gastrointestinal antigens. In the study by Tanner *et al.*^[97], they also found that there appeared to be fewer Tregs present in intestine from *mdr1a* KO mice and that these Tregs were unable to effectively suppress TNF- α induced colitis. These results are in accordance with the notion that inflammation primarily is initiated by the innate immune system.

In contradiction to the findings in the *Mdr1a* KO mice model, *Abcc2/Mrp2* KO and *Abcg2/Bcrp1* KO

mice were found to be phenotypically normal under standard housing conditions^[102,103].

The molecular mechanisms of ABC transporters may involve phospholipid transport

Cellular processes such as phagocytosis, apoptosis, cytokine release, vesicle formation and tight junction function require cell membrane budding and curvature and therefore, different composition of the inner and outer side of the lipid bilayer forming the cell membrane (Figure 1)^[104]. Translocation of phospholipids between the two sides of the lipid bilayer within the cell membrane is therefore important for generating such differences. ABCB1, ABCC2, and ABCG2 have been found to translocate various phospholipid membrane components; cholesterol, sphingomyelin, and other glycosphingolipids suggesting that ABC transporters are important for regulating the budding of the membrane function^[15,16,105,106]. Furthermore, the cellular processes also require cell cytoskeleton anchoring through specialised domains^[107]. ABCB1 has been

found to be associated with such domains^[106,108,109]. Other phospholipid transporters such as scramblases, P₄-ATPases and additional members of the ABC transporter family, are reviewed in^[15].

In vitro studies of rat kidney and Sertoli cells support the involvement of ABC transporters in tight junction function and apoptosis^[110,111]. At the Sertoli cell blood-testis barrier, ABCB1 was found to co-localise with occluding, claudin-11 and junction adhesion molecule A^[110]. Knockdown of *Abcb1* (*Abcb1a* and *Abcb1b*) by RNAi in rat Sertoli cell cultures led to a decline of claudin-11, internalisation and degradation of occluding, and disruption of tight junction barrier function^[110]. Another study found that ABCB1 decreased apoptosis by decreasing the availability of a precursor of ceramide^[111], an intracellular signalling molecule involved in apoptosis induced by TNF- α and other apoptotic stimuli^[106,108]. However, the functions of the ABC transporters may be tissue specific and therefore the results may not apply for intestinal conditions.

The molecular mechanisms of ABC transporters may be related to the transport of other substrates

Figure 1 shows mechanisms of substrate recognition and transport by ABC transporters^[16]. An *in vitro* study by Pawlik *et al.*^[112] on cultured peripheral blood mononuclear cells PBMC from healthy individuals found that stimulation with phytohaemagglutinin (PHA) leads to secretion of IL-2, IL-4, IL-6, IL-10, INF- γ , and TNF- α ^[112]. Furthermore, secretion of IL-2, IL-4, INF- γ , and TNF- α was inhibited by anti-MDR1 specific antibody whereas secretion of IL-6 and IL-10 was unaffected. In a similar study, blockade of ABCC1 by anti-MRP1 specific antibodies led to reversible abrogated cytokine secretion of IL-10, TNF- α , IL-4 and INF- γ ^[113]. However, another study using splenocytes from *Mdr1a* KO mice found that IL-2, IL-4, IL-10, and INF- γ secretion was independent of ABCB1. The authors suggested that ABCB1 may not be required for secretion of these cytokines because they contain a signal sequence designating the cytokines for secretion from the cells^[114]. Yet, a further *in vitro* study by Pawlik *et al.*^[115] on cultured PBMC, this time from 72 healthy *ABCB1* genotyped individuals was conducted. The cultured cells were stimulated with PHA and cytokines were measured in the supernatant. The authors found significantly lower concentration of IL-2, IL-4, INF- γ , and TNF- α , and unchanged concentration of IL-6 and IL-10 in cultured cells from individuals with *ABCB1* C3435T TT genotypes compared to CC genotypes^[115]. Also, ABCB1 blockade by the antagonist PSC833 resulted in impaired IL-12 secretion by antigen presenting cells from peripheral blood from healthy human volunteers suggesting that functional ABCB1 is required for IL-12 secretion in these cells^[116]. As previously mentioned, cytokines and chemokines are important modulators of intestinal inflammation and

carcinogenesis^[108,117]. Additionally, ABCB1, ABCC2, and ABCG2 also transport bioactive lipids^[15,16,105]. The levels of the ABCB1 substrate platelet-activating factor^[117-119] have been found to be high in intestinal mucosa from CD patients^[120]. PAF has been reported to regulate the function of tight junctions^[121] and to activate human neutrophils to extrusion of neutrophil extracellular traps (NETs) mediating extracellular capture and killing of bacteria^[122,123]. Also, ABCB1 has been reported to transport steroids, mineralocorticoids, androgens and oestrogens^[106]. Interestingly, the ABC substrate testosterone was found to be a key mediator of autoimmune responses in the non-obese diabetic mouse model of type 1 diabetes^[124]. Whether a similar phenomenon contributes to the observed male preponderance in *Mdr1a* KO IBD mouse model has not been studied as far as we know^[94]. ABCG2 transport the anti-inflammatory butyrate, a product of bacterial digestion of dietary fibres, and phytoestrogen from vegetables^[125,126]. ABCC2 has been reported to transport the pro-inflammatory signalling molecules leukotriene (LT) B₄ and LTC₄ involved in dendritic cell migration and CRC, and, furthermore, various diet- and smoke-derived carcinogens^[127-131]. Sulfasalazine and 5-aminosalicylic acid (5-ASA, mesalazine) are used for treatment and prevention of UC flares^[132]. ABCG2 is regarded as being the main transporter of sulfasalazine^[133,134] and ABCG2 activity has been suggested as having impact on sulfasalazine treatment efficacy in patients with rheumatoid arthritis (RA)^[135,136].

ABCB1 expression on T cells may identify pro-inflammatory Th17 cells

One study utilised ABCB1 expression to identify human Th17 cells with a unique pro-inflammatory transcriptional signature^[20]. This novel subset of Th17 cells, MDR1-positive Th17 cells, was identified by fluorescence activated cell sorting (FACS) analysis of PBMC from healthy individuals. Compared to MDR1-negative Th17 cells, the MDR1-positive Th17 cells were characterized by a high production of pro-inflammatory Th1 (INF- γ) and Th17 (IL-17A, IL-17F, and IL-22) cytokines and low levels of anti-inflammatory cytokines such as IL-10 upon stimulation^[20]. In contrast to the MDR1-negative T cells, the MDR1-positive T cells were resistant to treatment with glucocorticoids. Thus, MDR1-positive T cells from healthy humans were enriched two- to three-fold during culturing of peripheral blood memory T cells in the presence of glucocorticoids^[20]. Furthermore, in a small study of 3-5 CD patients, MDR1-positive Th17 cells (assessed as percent of the total number of memory cells) were enriched both in non-inflamed and inflamed gut tissue compared to blood levels^[20]. High mRNA levels of IFN- γ , IL23R, and TNF were found in MDR1-positive Th17 cells compared to MDR1-negative Th17 cells following FACS-sorting of mononuclear cells from gut tissue from two CD patients^[20].




Figure 2 Proposed mechanisms for the involvement of ABC transporters in intestinal inflammation.

DISCUSSION

The ABC transport proteins may confer a link between the environment and intestinal inflammation and potentially intestinal carcinogenesis *via* intestinal inflammation^[48-50,137,138]. Diet affects risk of CRC^[1], the course^[139-143] and risk of IBD^[144-148] (reviewed in^[149-153]). Diet affects gut microbial composition^[154,155] and both diet and intestinal microbes affect intestinal inflammation^[156,157] and carcinogenesis^[12,158-161].

A link between ABCB1, diet and the gut microbes in relation to colitis is suggested by the animal studies. High fat diet increases the frequency and severity of colitis in specific pathogen-free *Abcb1* KO mice^[100]. Undigested dietary items reaching the colon are digested by commensal bacteria thereby providing the host with valuable energy, essential vitamins, fatty acids etc. Dietary fibre from grains, fruit and vegetables is converted into short-chain fatty acids (SCFA) which represent important key regulators of the immune system^[12]. The gut microbiome in active IBD is characterised by decreased microbial diversity with a decreased number of Firmicutes^[162]. Low abundance of the *Clostridium* and *Bacteroides* species which preferentially produce butyrate and other SCFA may result in low production of SCFA^[163]. High intake of meat which is a rich source of sulphur may lead to the formation of hydrogen sulphide by bacterial fermentation^[12] which, at least theoretically, may be aggravated by high intake of milk fat which was found to favour the presence of the sulphate-reducing bacteria *Bilophila wadsworthia* in mice^[157]. Also, intake of animal fat may give rise to arachidonic acid which is converted into e.g., prostaglandins and

leukotrienes^[12]. Some of these molecules are ABC transporter substrates including dietary pro- and anti-inflammatory molecules, bioactive lipids, and bacterial derived molecules^[125,126]. Figure 2 shows potential mechanisms of the involvement of ABC transporters in inflammation. In addition, diet and other environmental factors may impact the transcriptional regulation of ABC transporters through effects on nuclear receptors and transcription factors leading to changes of the ABC transporter activity thereby affecting IBD and CRC. The ABC transporters may impact IBD and CRC through their transport of various substrates thereby affecting underlying biological mechanisms involved in intestinal inflammation (Figures 1 and 2).

ABC transporter polymorphisms have been evaluated in relation to development of IBD and CRC with inconsistent results. These studies are based on the hypothesis that genetic variations are associated with functional changes in ABC activity and/or specificity. It has been suggested that genetic diversity of the *ABCB1* gene among various ethnicities may contribute to the varying results in candidate gene studies^[164,165]. In addition, *ABCB1* polymorphisms may only be associated with risk of CRC in populations with a relevant dietary exposure^[166]. This aspect may be exemplified by the finding of an interaction between meat intake and the gene *NFKB1* encoding NF κ B p50 in a Danish cohort^[137]. This interaction may explain the finding that the *NFKB1* polymorphism was associated with risk of CRC in a Swedish cohort but not in a Chinese cohort^[167]. Meat intake are higher in Denmark and Sweden compared to China^[168]. Therefore, *NFKB1* was identified as a risk gene in the Danish and Swedish high meat intake cohorts but not in the Chinese low

meat intake cohort. A detailed assessment of the diet seems to be important for assessing the roles of ABC polymorphisms. Thus, future studies should focus on studying large cohorts with well-defined and relevant prospectively sampled environmental exposures in order to identify underlying IBD and CRC disease mechanisms.

Due to the many confounding parameters, potential causality cannot be evaluated through molecular epidemiological studies. Studies using animal models, where a range of parameters can be controlled are therefore needed for establishing causality. Germfree mice do not develop colitis. Although germfree mice are not exposed for living bacteria they will meet dietary derived microbial antigens which could activate PRR in the mucosa and induce inflammation. Inflammation, however, has not been observed in the germfree mice. Moreover, colitis can be prevented by antibiotics in conventionally housed, specific pathogen-free, mice. These findings suggest that microbial derived antigens are not sufficient to trigger colitis but that living microbes are needed and may thus point to potential mechanisms such as microbial derived metabolites, signalling peptides and extracellular vesicles^[169,170]. Indeed, gut microbial derived metabolites were found to affect the balance between pro- and anti-inflammatory cells in mice^[171]. These metabolites may be absorbed into the blood and thereby affect distant organs. Gut microbes have been reported to affect the immune system, in particular the Th17 pathway, in various autoimmune mouse models^[172-176]. Some studies, but not all^[177], indicate a similar mechanism in humans which might also associate with human autoimmunity^[178-180]. Also, bacterially derived fatty acids and other relevant metabolites should be investigated in the *Abcb1* KO mice like it has been done in male C57BL/6 (B6) mice^[171]. The *Abcb1* KO mice might provide a model, in which the interplay of environment factors, diet, and microbes can be controlled and investigated. Due to important differences of human and murine immune systems, the translational value of results obtained from the mouse model need also to be evaluated through human data.

The finding that presence of ABCB1 on immune cells could be used to identify pro-inflammatory Th17 cells may have important clinical implications as glucocorticoids are a mainstay in the treatment of serious flares of IBD^[181] and since a large proportion (20%-30%) of patients are resistant to glucocorticoid treatment^[182]. Thus, high ABCB1 mediated drug efflux may lead to decreased intracellular drug concentrations in target cells^[183,184] and thereby confer glucocorticoid treatment resistance. Likewise, ABCG2 activity may affect efficacy of treatment with sulfasalazine. Further evaluation of the roles of ABC transporters in treatment response in IBD is warranted.

In conclusion, results from animal and human studies indicate that ABCB1, diet, and gut microbes

mutually interact in colonic inflammation. Diet and microbes may give rise to molecules which are substrates for the ABC transporters and may additionally affect ABC transporter function through *e.g.*, nuclear receptors and transcriptional regulation. The *Abcb1* KO mice might provide a model in which these factors can be controlled and investigated. Such strategy may provide insight which can be translated into preventive and treatment strategies to benefit the patients. The evidence for the involvement of ABCG2 and ABCG2 in colitis was weak.

ACKNOWLEDGMENTS

Staff at the Libraries, Regional Hospital Viborg and Hospital of Southern Denmark, are thanked for help.

COMMENTS

Background

Colorectal cancer (CRC) constitutes the third most common cancer in the world and the second leading cause of cancer-related deaths. The number of cases is increasing and has been estimated to raise from 1.4 million cases in 2012 to 2.4 million cases in 2035 worldwide. Early detection of CRC is important as early treatment has been associated with improved outcomes and saved lives. Therefore, population screening programs have been initiated in a number of countries such as the United Kingdom, Australia, Holland and Denmark. The fecal occult blood test (FOBT) is the most widely used for population screening and individuals with a positive FOBT are referred for an endoscopic investigation of the colonic mucosa thereby enabling the sampling of biopsies from the colonic mucosa.

Research frontiers

Recently, a major part of research had focused on improving prognosis and treatment selection in CRC. Another approach could be to prevent the development of cancer in subgroups of patients with high risk, *i.e.*, secondary prevention. Thus, the molecular evaluation of the (unaffected) colonic mucosa from the patients undergoing an endoscopic evaluation could potentially stratify the patients according to their risk of developing CRC. Recently, human studies by authors reported that changes in the levels of ABC transporters were early events in the adenoma-carcinoma sequence leading to CRC. These findings indicate that even healthy looking mucosa as determined by histology may contain a significantly elevated level of immune response proteins.

Innovations and breakthroughs

The authors recently reported that low ABCB1 and ABCG2 gene transcription levels and high ABCG2 levels are early events in the colorectal adenoma-carcinoma sequence suggesting that changes in expression levels of the ATP binding cassette (ABC) transporter proteins [EC 3.6.3.44] precede cancer development. In addition, inflammatory bowel disease (IBD) may be a risk factor for the development of CRC. Therefore, the authors wanted to discuss the current understanding of how these ABC transporters may affect intestinal inflammation and carcinogenesis, how they may potentially interact with the environment such as diet and gut microbes, and whether this knowledge may be utilized for improved treatment care strategies. A link between ABCB1, high fat diet and gut microbes in relation to colitis was suggested by the animal studies. The *Abcb1* KO mice might thus serve as a model in which diet/environmental factors and microbes may be controlled and investigated in relation to intestinal inflammation. Such strategy may provide insight which can be translated into preventive and treatment strategies to benefit the patients.

Applications

Biomarkers potentially predicting the disease risk among selected patient groups could improve the efficiency of the screening programs and patient care. Furthermore, they have the potential to dramatically alter the established

patient care pathways as follow-up of the patients may be tailored according to their individual risk and thereby the organization and use of resources of the health care system.

Peer-review

Congratulations to the authors for their review on ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. It is certain that this paper will be very inspiring in this field. Personally recommend it to be accepted.

REFERENCES

- 1 WCRF. World Cancer Research Fund International. Available from: URL: <http://www.wcrf.org/> 2014
- 2 UEG. Colorectal cancer in Europe. Available from: URL: <http://www.ueg.eu/press/crceurope/> 2014
- 3 CRC screening UK. Available from: URL: <http://www.cancer-screening.nhs.uk/bowel/>.
- 4 CRC screening Australia. Available from: URL: <http://www.bowelcanceraustralia.org/>
- 5 CRC screening the Netherlands. Available from: URL: http://www.rivm.nl/Onderwerpen/B/Bevolkingsonderzoek_darmkanker.
- 6 CRC screening DK. Available from: URL: <http://www.sundhed.dk/borger/sundhedsjournal-og-registreringer/tilmeldinger/screeningsprogrammer/tarmkraeftscreening/>
- 7 Huddy JR, Ni MZ, Markar SR, Hanna GB. Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions. *World J Gastroenterol* 2015; **21**: 4111-4120 [PMID: 25892860 DOI: 10.3748/wjg.v21.i14.4111]
- 8 Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. *Int J Cancer* 2014; **134**: 2513-2522 [PMID: 23852704 DOI: 10.1002/ijc.28384]
- 9 Koch C, Trojan J. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond. *Digestion* 2015; **91**: 294-302 [PMID: 25924988 DOI: 10.1159/000376573]
- 10 Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. *World J Gastroenterol* 2014; **20**: 3858-3874 [PMID: 24744578 DOI: 10.3748/wjg.v20.i14.3858]
- 11 Bennike TB, Carlsen TG, Ellingsen T, Bonderup OK, Glerup H, Bøgsted M, Christiansen G, Birkelund S, Stensballe A, Andersen V. Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies. *Inflamm Bowel Dis* 2015; **21**: 2052-2067 [PMID: 25993694 DOI: 10.1097/MIB.0000000000000460]
- 12 Andersen V, Vogel U. Dietary fibres and meat in relation to Colorectal Cancer. *Norske Gastroenterologisk Forening-nytt* 2014: 34-36
- 13 Andersen V, Vogel U, Godiksen S, Frenzel FB, Sæbø M, Hamfjord J, Kure E, Vogel LK. Low ABCB1 gene expression is an early event in colorectal carcinogenesis. *PLoS One* 2013; **8**: e72119 [PMID: 23977225 DOI: 10.1371/journal.pone.0072119]
- 14 Andersen V, Vogel LK, Kopp TI, Sæbø M, Nonboe AW, Hamfjord J, Kure EH, Vogel U. High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence. *PLoS One* 2015; **10**: e0119255 [PMID: 25793771 DOI: 10.1371/journal.pone.0119255]
- 15 Coleman JA, Quazi F, Molday RS. Mammalian P4-ATPases and ABC transporters and their role in phospholipid transport. *Biochim Biophys Acta* 2013; **1831**: 555-574 [PMID: 23103747 DOI: 10.1016/j.bbali.2012.10.006]
- 16 Tarling EJ, de Aguiar Vallim TQ, Edwards PA. Role of ABC transporters in lipid transport and human disease. *Trends Endocrinol Metab* 2013; **24**: 342-350 [PMID: 23415156 DOI: 10.1016/j.tem.2013.01.006]
- 17 Mack JT, Beljanski V, Tew KD, Townsend DM. The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. *Biomed Pharmacother* 2006; **60**: 587-592 [PMID: 17029687 DOI: 10.2174/138161211797440221]
- 18 Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. *J Am Coll Cardiol* 2013; **61**: 2495-2502 [PMID: 23563132 DOI: 10.1016/j.jacc.2013.02.058]
- 19 Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. *J Drug Target* 2012; **20**: 736-763 [PMID: 22994411 DOI: 10.3109/1061186X.2012.716847]
- 20 Ramesh R, Kozhaya L, McKeivitt K, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, Abreu MT, Unutmaz D, Sundrud MS. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. *J Exp Med* 2014; **211**: 89-104 [PMID: 24395888 DOI: 10.1084/jem.20130301]
- 21 Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. *Gen Pharmacol* 1996; **27**: 1283-1291 [PMID: 9304397 DOI: 10.1080/00498250701867889]
- 22 Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu Rev Pharmacol Toxicol* 1999; **39**: 361-398 [PMID: 10331089 DOI: 10.1146/annurev.pharmtox.39.1.361]
- 23 Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. *Toxicol Appl Pharmacol* 2005; **204**: 216-237 [PMID: 15845415 DOI: 10.1016/j.taap.2004.10.012]
- 24 Abu-Qare AW, Elmasry E, Abou-Donia MB. A role for P-glycoprotein in environmental toxicology. *J Toxicol Environ Health B Crit Rev* 2003; **6**: 279-288 [PMID: 12746142 DOI: 10.1080/10937400306466]
- 25 Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. *Adv Drug Deliv Rev* 2003; **55**: 3-29 [PMID: 12535572 DOI: 10.1016/S0169-409X(02)00169-2]
- 26 Sarkadi B, Homolya L, Szakács G, Váradi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoinmunity defense system. *Physiol Rev* 2006; **86**: 1179-1236 [PMID: 17015488 DOI: 10.1152/physrev.00037.2005]
- 27 Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. *Cell* 1991; **66**: 85-94 [PMID: 1712673 DOI: 10.1016/0092-8674(91)90141-K]
- 28 Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? *Gut* 2003; **52**: 759-766 [PMID: 12692067 DOI: 10.1136/gut.52.5.759]
- 29 Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. *Curr Drug Metab* 2004; **5**: 21-53 [PMID: 14965249 DOI: 10.2174/1389200043489199]
- 30 Stefková J, Poledne R, Hubáček JA. ATP-binding cassette (ABC) transporters in human metabolism and diseases. *Physiol Res* 2004; **53**: 235-243 [PMID: 15209530]
- 31 Specia S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. *World J Gastroenterol* 2012; **18**: 3635-3661 [PMID: 22851857 DOI: 10.3748/wjg.v18.i28.3635]
- 32 Basseri RJ, Basseri B, Papadakis KA. Dysplasia and cancer in inflammatory bowel disease. *Expert Rev Gastroenterol Hepatol* 2011; **5**: 59-66 [PMID: 21309672 DOI: 10.1124/dmd.113.055772]
- 33 Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. *J Agric Food Chem* 2008; **56**: 5366-5373 [PMID: 18540626 DOI: 10.1021/jf073350e]
- 34 Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. *Adv Drug Deliv Rev* 2010; **62**: 1238-1249 [PMID: 20727377 DOI: 10.1016/j.addr.2010.08.006]
- 35 Wang K, Wan YJ. Nuclear receptors and inflammatory diseases. *Exp Biol Med (Maywood)* 2008; **233**: 496-506 [PMID: 18375823 DOI: 10.3181/0708-MR-231]
- 36 Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C,

- Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. *Biochem Pharmacol* 2005; **70**: 949-958 [PMID: 16054595 DOI: 10.1016/j.bcp.2005.06.018]
- 37 Tachibana S, Yoshinari K, Chikada T, Toriyabe T, Nagata K, Yamazoe Y. Involvement of Vitamin D receptor in the intestinal induction of human ABCB1. *Drug Metab Dispos* 2009; **37**: 1604-1610 [PMID: 19460946 DOI: 10.1124/dmd.109.027219]
- 38 Wang X, Hawkins BT, Miller DS. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. *FASEB J* 2011; **25**: 644-652 [PMID: 21048045 DOI: 10.1096/fj.10-169227]
- 39 Blokzijl H, Vander Borgh S, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, Faber KN. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. *Inflamm Bowel Dis* 2007; **13**: 710-720 [PMID: 17262809 DOI: 10.1002/ibd.20088]
- 40 Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. *Gastroenterology* 2004; **127**: 26-40 [PMID: 15236169 DOI: 10.1053/j.gastro.2004.04.019]
- 41 Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. *Trends Pharmacol Sci* 2010; **31**: 246-254 [PMID: 20417575 DOI: 10.1016/j.tips.2010.03.003]
- 42 Chakraborty PK, Lee WK, Molitor M, Wolff NA, Thévenod F. Cadmium induces Wnt signaling to upregulate proliferation and survival genes in sub-confluent kidney proximal tubule cells. *Mol Cancer* 2010; **9**: 102 [PMID: 20459685 DOI: 10.1186/1476-4598-9-102]
- 43 Chambers TC, Pohl J, Glass DB, Kuo JF. Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. *Biochem J* 1994; **299** (Pt 1): 309-315 [PMID: 7909431]
- 44 Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. *Mol Pharmacol* 2010; **78**: 310-318 [PMID: 20460432 DOI: 10.1124/mol.109.061713]
- 45 Begley GS, Horvath AR, Taylor JC, Higgins CF. Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. *Mol Immunol* 2005; **42**: 137-141 [PMID: 15488952 DOI: 10.1016/j.jcanlet.2013.12.007]
- 46 Goel A, Boland CR. Recent insights into the pathogenesis of colorectal cancer. *Curr Opin Gastroenterol* 2010; **26**: 47-52 [PMID: 19786869 DOI: 10.1097/MOG.0b013e328332b850]
- 47 Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut* 2011; **60**: 397-411 [PMID: 21036793 DOI: 10.1136/gut.2010.217182]
- 48 Collett A, Higgs NB, Gironella M, Zeef LA, Hayes A, Salmo E, Haboubi N, Iovanna JL, Carlson GL, Warhurst G. Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in *mdr1a(-/-)* mice. *Inflamm Bowel Dis* 2008; **14**: 620-631 [PMID: 18275070 DOI: 10.1586/egh.10.77]
- 49 McConnell BB, Yang VW. The Role of Inflammation in the Pathogenesis of Colorectal Cancer. *Curr Colorectal Cancer Rep* 2009; **5**: 69-74 [PMID: 19756239 DOI: 10.1007/s11888-009-0011-z]
- 50 Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. *Trends Mol Med* 2002; **8**: 10-16 [PMID: 11796261 DOI: 10.1016/S1471-4914(01)02194-3]
- 51 Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. *Lancet* 2007; **369**: 1627-1640 [PMID: 17499605 DOI: 10.1016/S0140-6736(07)60750-8]
- 52 Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. *J Clin Invest* 2007; **117**: 514-521 [PMID: 17332878 DOI: 10.1172/JCI30587]
- 53 Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. *Am J Gastroenterol* 2013; **108**: 1869-1876 [PMID: 23978954 DOI: 10.1038/ajg.2013.249]
- 54 Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. *J Crohns Colitis* 2013; **7**: 1-33 [PMID: 23040453 DOI: 10.1016/j.crohns.2012.09.003]
- 55 Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]
- 56 Denson LA. The role of the innate and adaptive immune system in pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 2013; **19**: 2011-2020 [PMID: 23702804 DOI: 10.3389/fimmu.2013.00280]
- 57 Marchiando AM, Shen L, Graham WV, Edelblum KL, Duckworth CA, Guan Y, Montrose MH, Turner JR, Watson AJ. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. *Gastroenterology* 2011; **140**: 1208-1218.e1-2 [PMID: 21237166 DOI: 10.1053/j.gastro.2011.01.004]
- 58 Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature* 2011; **474**: 298-306 [PMID: 21677746 DOI: 10.1038/nature10208]
- 59 Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. *Nat Immunol* 2012; **13**: 325-332 [PMID: 22430785 DOI: 10.1038/ni.2231]
- 60 Chen GY, Núñez G. Inflammasomes in intestinal inflammation and cancer. *Gastroenterology* 2011; **141**: 1986-1999 [PMID: 22005480 DOI: 10.1053/j.gastro.2011.10.002]
- 61 Delgado M, Singh S, De Haro S, Master S, Ponpuak M, Dinkins C, Ornatowski W, Vergne I, Deretic V. Autophagy and pattern recognition receptors in innate immunity. *Immunol Rev* 2009; **227**: 189-202 [PMID: 19120485 DOI: 10.1111/j.1600-065X.2008.00725.x]
- 62 Delgado ME, Dyck L, Laussmann MA, Rehm M. Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways. *Cell Death Dis* 2014; **5**: e1011 [PMID: 24457955 DOI: 10.1038/cddis.2013.520]
- 63 Turner JR. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol* 2009; **9**: 799-809 [PMID: 19855405 DOI: 10.1136/gutjnl-2012-303955]
- 64 MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. *Gastroenterology* 2011; **140**: 1768-1775 [PMID: 21530743 DOI: 10.1053/j.gastro.2011.02.047]
- 65 Wedebye Schmidt EG, Larsen HL, Kristensen NN, Poulsen SS, Lyng Pedersen AM, Claesson MH, Pedersen AE. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. *Inflamm Bowel Dis* 2013; **19**: 1567-1576 [PMID: 23689808 DOI: 10.1097/MIB.0b013e318286fa1c]
- 66 Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, Corazza GR, Monteleone G, Di Sabatino A, Macdonald TT. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. *Gut* 2009; **58**: 1629-1636 [PMID: 19740775 DOI: 10.1136/gut.2009.182170]
- 67 Xie Z, Qu Y, Leng Y, Sun W, Ma S, Wei J, Hu J, Zhang X. Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses. *Drug Des Devel Ther* 2015; **9**: 1679-1689 [PMID: 25834404 DOI: 10.2147/DDDT.S79431]
- 68 Busman-Sahay KO, Walrath T, Huber S, O'Connor W. Cytokine

- crowdsourcing: multicellular production of TH17-associated cytokines. *J Leukoc Biol* 2015; **97**: 499-510 [PMID: 25548251 DOI: 10.1189/jlb.3RU0814-386R]
- 69 **Ueno A**, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, Beck PL, Iacucci M, Fort Gasia M, Barkema HW, Panaccione R, Ghosh S. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. *Inflamm Bowel Dis* 2013; **19**: 2522-2534 [PMID: 24097227 DOI: 10.1097/MIB.0b013e3182a85709]
- 70 **ten Hove T**, Drillenburger P, Wijnholds J, Te Velde AA, van Deventer SJ. Differential susceptibility of multidrug resistance protein-1 deficient mice to DSS and TNBS-induced colitis. *Dig Dis Sci* 2002; **47**: 2056-2063 [PMID: 12353855 DOI: 10.1189/jlb.1RU0114-010RR]
- 71 **Sarrabayrouse G**, Bossard C, Chauvin JM, Jarry A, Meurette G, Quévrain E, Bridonneau C, Preisser L, Asehnoune K, Labarrière N, Altare F, Sokol H, Jotereau F. CD4CD8 α lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. *PLoS Biol* 2014; **12**: e1001833 [PMID: 24714093 DOI: 10.1371/journal.pbio.1001833]
- 72 **Englund G**, Jacobson A, Rorsman F, Artursson P, Kindmark A, Rönnblom A. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). *Inflamm Bowel Dis* 2007; **13**: 291-297 [PMID: 17206689 DOI: 10.1002/ibd.20030]
- 73 **Deuring JJ**, de Haar C, Koelewijn CL, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding. *Biochem J* 2012; **441**: 87-93 [PMID: 21864296 DOI: 10.1042/bj20111281]
- 74 **Deuring JJ**, Peppelenbosch MP, Kuipers EJ, van der Woude CJ, de Haar C. Impeded protein folding and function in active inflammatory bowel disease. *Biochem Soc Trans* 2011; **39**: 1107-1111 [PMID: 21787357 DOI: 10.1042/bst0391107]
- 75 **Østergaard M**, Ernst A, Labouriau R, Dagilienė E, Krapup HB, Christensen M, Thorsgaard N, Jacobsen BA, Tage-Jensen U, Overvad K, Autrup H, Andersen V. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. *Scand J Gastroenterol* 2009; **44**: 65-73 [PMID: 18819034 DOI: 10.1080/00365520802400826]
- 76 **Ho GT**, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. *Hum Mol Genet* 2006; **15**: 797-805 [PMID: 16434479 DOI: 10.1093/hmg/ddi494]
- 77 **Ho GT**, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott ID, Satsangi J. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. *Gastroenterology* 2005; **128**: 288-296 [PMID: 15685540 DOI: 10.1053/j.gastro.2004.11.019]
- 78 **Brant SR**, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. *Am J Hum Genet* 2003; **73**: 1282-1292 [PMID: 14610718 DOI: 10.1086/379927]
- 79 **Schwab M**, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. *Gastroenterology* 2003; **124**: 26-33 [PMID: 12512026 DOI: 10.1053/gast.2003.50010]
- 80 **Andersen V**, Egeberg R, Tjønneland A, Vogel U. ABCC2 transporter gene polymorphisms, diet and risk of colorectal cancer: a Danish prospective cohort study. *Scand J Gastroenterol* 2012; **47**: 572-574 [PMID: 22428913 DOI: 10.3109/00365521.2012.668933]
- 81 **Campa D**, Pardini B, Naccarati A, Vodickova L, Novotny J, Försti A, Hemminki K, Barale R, Vodicka P, Canzian F. A gene-wide investigation on polymorphisms in the ABCG2/BRCP transporter and susceptibility to colorectal cancer. *Mutat Res* 2008; **645**: 56-60 [PMID: 18775442 DOI: 10.1016/j.mrfmmm.2008.08.001]
- 82 **Andersen V**, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. *BMC Cancer* 2009; **9**: 407 [PMID: 19930591 DOI: 10.1186/1471-2407-9-407]
- 83 **Annese V**, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. *World J Gastroenterol* 2006; **12**: 3636-3644 [PMID: 16773678 DOI: 10.3748/wjg.v12.i23.3636]
- 84 **Wang LH**, Song YB, Zheng WL, Jiang L, Ma WL. The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies. *Cancer Cell Int* 2013; **13**: 46 [PMID: 23687985 DOI: 10.1002/ibd.21728]
- 85 **He T**, Mo A, Zhang K, Liu L. ABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta-analysis of case-control studies. *Colorectal Dis* 2013; **15**: 12-18 [PMID: 23279665 DOI: 10.1111/j.1463-1318.2012.02919.x]
- 86 **Fung KL**, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. *Biochim Biophys Acta* 2009; **1794**: 860-871 [PMID: 19285158 DOI: 10.1016/j.bbapap.2009.02.014]
- 87 **Fung KL**, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. *Cancer Res* 2014; **74**: 598-608 [PMID: 24305879 DOI: 10.1158/0008-5472.CAN-13-2064]
- 88 **Campa D**, Sainz J, Pardini B, Vodickova L, Naccarati A, Rudolph A, Novotny J, Försti A, Buch S, von Schönfels W, Schafmayer C, Völzke H, Hoffmeister M, Frank B, Barale R, Hemminki K, Hampe J, Chang-Claude J, Brenner H, Vodicka P, Canzian F. A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. *PLoS One* 2012; **7**: e32784 [PMID: 22396794 DOI: 10.1371/journal.pone.0032784]
- 89 **Borst P**, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. *J Clin Invest* 2013; **123**: 4131-4133 [PMID: 24084745 DOI: 10.1172/JCI70430]
- 90 **Cui YJ**, Cheng X, Weaver YM, Klaassen CD. Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. *Drug Metab Dispos* 2009; **37**: 203-210 [PMID: 18854377 DOI: 10.1124/dmd.108.023721]
- 91 **Panwala CM**, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. *J Immunol* 1998; **161**: 5733-5744 [PMID: 9820555]
- 92 **Staley EM**, Schoeb TR, Lorenz RG. Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults. *Inflamm Bowel Dis* 2009; **15**: 684-696 [PMID: 19067430 DOI: 10.1002/ibd.20824]
- 93 **Staley EM**, Yarbrough VR, Schoeb TR, Daft JG, Tanner SM, Steverson D, Lorenz RG. Murine P-glycoprotein deficiency alters intestinal injury repair and blunts lipopolysaccharide-induced radioprotection. *Radiat Res* 2012; **178**: 207-216 [PMID: 22780103 DOI: 10.1667/RR2835.1]
- 94 **Pastorelli L**, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. *Front Immunol* 2013; **4**: 280 [PMID: 24062746 DOI: 10.1155/ajpgi.00395.2004]
- 95 **Nones K**, Knoch B, Dommels YE, Paturi G, Butts C, McNabb WC, Roy NC. Multidrug resistance gene deficient (mdr1a $-/-$) mice have an altered caecal microbiota that precedes the onset of intestinal inflammation. *J Appl Microbiol* 2009; **107**: 557-566

- [PMID: 19302324 DOI: 10.1111/j.1365-2672.2009.04225.x]
- 96 **Staley EM**, Dimmitt RA, Schoeb TR, Tanner SM, Lorenz RG. Critical role for P-glycoprotein expression in hematopoietic cells in the FVB.Mdr1a(-/-) model of colitis. *J Pediatr Gastroenterol Nutr* 2011; **53**: 666-673 [PMID: 21681110 DOI: 10.1097/MPG.0b013e31822860f1]
 - 97 **Tanner SM**, Staley EM, Lorenz RG. Altered generation of induced regulatory T cells in the FVB.mdr1a-/- mouse model of colitis. *Mucosal Immunol* 2013; **6**: 309-323 [PMID: 22874899 DOI: 10.1038/mi.2012.73]
 - 98 **Low D**, Nguyen DD, Mizoguchi E. Animal models of ulcerative colitis and their application in drug research. *Drug Des Devel Ther* 2013; **7**: 1341-1357 [PMID: 24250223 DOI: 10.1002/ibd.20375]
 - 99 **Maggio-Price L**, Bielefeldt-Ohmann H, Treuting P, Iritani BM, Zeng W, Nicks A, Tsang M, Shows D, Morrissey P, Viney JL. Dual infection with *Helicobacter bilis* and *Helicobacter hepaticus* in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia. *Am J Pathol* 2005; **166**: 1793-1806 [PMID: 15920164 DOI: 10.1016/S0002-9440(10)62489-3]
 - 100 **Paik J**, Fierce Y, Treuting PM, Brabb T, Maggio-Price L. High-fat diet-induced obesity exacerbates inflammatory bowel disease in genetically susceptible Mdr1a-/- male mice. *J Nutr* 2013; **143**: 1240-1247 [PMID: 23761644 DOI: 10.3945/jn.113.174615]
 - 101 **Ellinghaus D**, Zhang H, Zeissig S, Lipinski S, Till A, Jiang T, Stade B, Bromberg Y, Ellinghaus E, Keller A, Rivas MA, Skieceviciene J, Doncheva NT, Liu X, Liu Q, Jiang F, Forster M, Mayr G, Albrecht M, Häsler R, Boehm BO, Goodall J, Berzuini CR, Lee J, Andersen V, Vogel U, Kupcinkas L, Kayser M, Krawczak M, Nikolaus S, Weersma RK, Ponsioen CY, Sans M, Wijmenga C, Strachan DP, McArdle WL, Vermeire S, Rutgeerts P, Sanderson JD, Mathew CG, Vatn MH, Wang J, Nöthen MM, Duerr RH, Büning C, Brand S, Glas J, Winkelmann J, Illig T, Latiano A, Annese V, Halfvarson J, D'Amato M, Daly MJ, Nothnagel M, Karlsen TH, Subramani S, Rosenstiel P, Schreiber S, Parkes M, Franke A. Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. *Gastroenterology* 2013; **145**: 339-347 [PMID: 23624108 DOI: 10.1053/j.gastro.2013.04.040]
 - 102 **Jonker JW**, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. *Proc Natl Acad Sci USA* 2002; **99**: 15649-15654 [PMID: 12429862 DOI: 10.1073/pnas.202607599]
 - 103 **Kruh GD**, Belinsky MG, Gallo JM, Lee K. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. *Cancer Metastasis Rev* 2007; **26**: 5-14 [PMID: 17273943 DOI: 10.1007/s10555-007-9039-1]
 - 104 **Goñi FM**. The basic structure and dynamics of cell membranes: an update of the Singer-Nicolson model. *Biochim Biophys Acta* 2014; **1838**: 1467-1476 [PMID: 24440423 DOI: 10.1016/j.bbame.2014.01.006]
 - 105 **Quazi F**, Molday RS. Lipid transport by mammalian ABC proteins. *Essays Biochem* 2011; **50**: 265-290 [PMID: 21967062 DOI: 10.1042/bse0500265]
 - 106 **Aye IL**, Singh AT, Keelan JA. Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function. *Chem Biol Interact* 2009; **180**: 327-339 [PMID: 19426719 DOI: 10.1016/j.cbi.2009.04.012]
 - 107 **McDaniel K**, Correa R, Zhou T, Johnson C, Francis H, Glaser S, Venter J, Alpini G, Meng F. Functional role of microvesicles in gastrointestinal malignancies. *Ann Transl Med* 2013; **1**: 4 [PMID: 24432300 DOI: 10.3978/j.issn.2305-5839.2012.10.01]
 - 108 **Johnstone RW**, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? *Trends Biochem Sci* 2000; **25**: 1-6 [PMID: 10637601 DOI: 10.1016/S0968-0004(99)01493-0]
 - 109 **Klappe K**, Hummel I, Hoekstra D, Kok JW. Lipid dependence of ABC transporter localization and function. *Chem Phys Lipids* 2009; **161**: 57-64 [PMID: 19651114 DOI: 10.1016/j.chemphyslip.2009.07.004]
 - 110 **Su L**, Mruk DD, Lui WY, Lee WM, Cheng CY. P-glycoprotein regulates blood-testis barrier dynamics via its effects on the occludin/zonula occludens 1 (ZO-1) protein complex mediated by focal adhesion kinase (FAK). *Proc Natl Acad Sci USA* 2011; **108**: 19623-19628 [PMID: 22106313 DOI: 10.1073/pnas.1111414108]
 - 111 **Dimeloe S**, Frick C, Fischer M, Gubser PM, Razik L, Bantug GR, Ravon M, Langenkamp A, Hess C. Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. *Eur J Immunol* 2014; **44**: 3614-3620 [PMID: 25251877 DOI: 10.1093/toxsci/kfr071]
 - 112 **Pawlik A**, Baškiewicz-Masiuk M, Machaliński B, Safranow K, Gawrońska-Szklarz B. Involvement of P-glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. *J Pharm Pharmacol* 2005; **57**: 1421-1425 [PMID: 16259774 DOI: 10.1211/jpp.57.11.0007]
 - 113 **Veldhoen M**, Brucklacher-Waldert V. Dietary influences on intestinal immunity. *Nat Rev Immunol* 2012; **12**: 696-708 [PMID: 23007570 DOI: 10.1093/intimm/dxh389]
 - 114 **Gollapudi S**, Kim C, Gupta S. P-glycoprotein (encoded by multidrug resistance genes) is not required for interleukin-2 secretion in mice and humans. *Genes Immun* 2000; **1**: 371-379 [PMID: 11196684 DOI: 10.1038/sj.gene.6363693]
 - 115 **Pawlik A**, Baškiewicz-Masiuk M, Machaliński B, Kurzawski M, Gawronska-Szklarz B. Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. *Eur J Pharmacol* 2005; **528**: 27-36 [PMID: 16321374 DOI: 10.1016/j.ejphar.2005.10.068]
 - 116 **Pendse SS**, Behjati S, Schatton T, Izawa A, Sayegh MH, Frank MH. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. *Am J Transplant* 2006; **6**: 2884-2893 [PMID: 17083370 DOI: 10.1111/j.1600-6143.2006.01561.x]
 - 117 **Raggers RJ**, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. *Biochem J* 2001; **357**: 859-865 [PMID: 11463358 DOI: 10.1042/0264-6021.]
 - 118 **Papafili A**, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. *Arterioscler Thromb Vasc Biol* 2002; **22**: 1631-1636 [PMID: 12377741 DOI: 10.1161/01.ATV.0000030340.80207.C5]
 - 119 **Bosch I**, Dunussi-Joannopoulos K, Wu RL, Furlong ST, Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. *Biochemistry* 1997; **36**: 5685-5694 [PMID: 9153408 DOI: 10.1021/bi962728r]
 - 120 **Sobhani I**, Hochlaf S, Denizot Y, Vissuzaine C, Rene E, Benveniste J, Lewin MM, Mignon M. Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. *Gut* 1992; **33**: 1220-1225 [PMID: 1427375 DOI: 10.1136/gut.33.9.1220]
 - 121 **Xu LF**, Teng X, Guo J, Sun M. Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor. *Inflammation* 2012; **35**: 308-315 [PMID: 21452036 DOI: 10.1007/s10753-011-9320-x]
 - 122 **Kaplan MJ**, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. *J Immunol* 2012; **189**: 2689-2695 [PMID: 22956760 DOI: 10.1371/journal.pone.0075664]
 - 123 **Yost CC**, Weyrich AS, Zimmerman GA. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. *Biochimie* 2010; **92**: 692-697 [PMID: 20167241 DOI: 10.4049/jimmunol.1201719]
 - 124 **Flak MB**, Neves JF, Blumberg RS. Immunology. Welcome to the microgenome. *Science* 2013; **339**: 1044-1045 [PMID: 23449586 DOI: 10.1126/science.1233521]
 - 125 **van de Wetering K**, Saptho S. ABCG2 functions as a general phytoestrogen sulfate transporter in vivo. *FASEB J* 2012; **26**: 4014-4024 [PMID: 22707564 DOI: 10.1096/fj.12-210039]

- 126 **Gonçalves P**, Gregório I, Martel F. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. *Am J Physiol Cell Physiol* 2011; **301**: C984-C994 [PMID: 21775706]
- 127 **Randolph GJ**. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. *Semin Immunol* 2001; **13**: 267-274 [PMID: 11502161 DOI: 10.1006/smim.2001.0322]
- 128 **Dietrich CG**, de Waart DR, Ottenhoff R, Bootsma AH, van Gennip AH, Elferink RP. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. *Carcinogenesis* 2001; **22**: 805-811 [PMID: 11323401 DOI: 10.1093/carcin/22.5.805]
- 129 **Deeley RG**, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). *FEBS Lett* 2006; **580**: 1103-1111 [PMID: 16387301 DOI: 10.1016/j.febslet.2005.12.036]
- 130 **Jedlitschky G**, Keppler D. Transport of leukotriene C4 and structurally related conjugates. *Vitam Horm* 2002; **64**: 153-184 [PMID: 11898391 DOI: 10.1016/S0083-6729(02)64005-1]
- 131 **Wang D**, Dubois RN. Eicosanoids and cancer. *Nat Rev Cancer* 2010; **10**: 181-193 [PMID: 20168319 DOI: 10.1038/nrc2809]
- 132 **Harris MS**, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. *Aliment Pharmacol Ther* 2011; **33**: 996-1009 [PMID: 21385194 DOI: 10.1111/j.1365-2036.2011.04619.x]
- 133 **Urqhart BL**, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. *Pharmacogenet Genomics* 2008; **18**: 439-448 [PMID: 18408567 DOI: 10.1097/FPC.0b013e3282f974dc]
- 134 **Zaher H**, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. *Mol Pharm* 2006; **3**: 55-61 [PMID: 16686369 DOI: 10.1021/mp050113v]
- 135 **van der Heijden J**, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, Schalkwijk CG, Scheffer GL, Scheper R, Jansen G. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. *Ann Rheum Dis* 2004; **63**: 138-143 [PMID: 14722201 DOI: 10.1136/ard.2002.005249]
- 136 **Furst DE**. Acquired resistance of human T cells to sulfasalazine. *Ann Rheum Dis* 2004; **63**: 115-116 [PMID: 14722196 DOI: 10.1136/ard.2003.014613]
- 137 **Andersen V**, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in Nfkb, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. *BMC Cancer* 2010; **10**: 484 [PMID: 20836841 DOI: 10.1186/1471-2407-10-484]
- 138 **Kopp TI**, Andersen V, Tjønneland A, Vogel U. Polymorphisms in NFKB1 and TLR4 and interaction with dietary and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. *PLoS One* 2015; **10**: e0116394 [PMID: 25705893 DOI: 10.1371/journal.pone.0116394]
- 139 **Herfarth HH**, Martin CF, Sandler RS, Kappelman MD, Long MD. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. *Inflamm Bowel Dis* 2014; **20**: 1194-1197 [PMID: 24865778 DOI: 10.1097/mib.0000000000000077]
- 140 **Cohen AB**, Lee D, Long MD, Kappelman MD, Martin CF, Sandler RS, Lewis JD. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. *Dig Dis Sci* 2013; **58**: 1322-1328 [PMID: 22923336 DOI: 10.1007/s00384-012-1587-3]
- 141 **Jowett SL**, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. *Gut* 2004; **53**: 1479-1484 [PMID: 15361498 DOI: 10.1136/gut.2003.024828]
- 142 **Gearty RB**, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. *J Crohns Colitis* 2009; **3**: 8-14 [PMID: 21172242 DOI: 10.1016/j.crohns.2008.09.004]
- 143 **Kyaw MH**, Moshkovska T, Mayberry J. A prospective, randomized, controlled, exploratory study of comprehensive dietary advice in ulcerative colitis: impact on disease activity and quality of life. *Eur J Gastroenterol Hepatol* 2014; **26**: 910-917 [PMID: 24942954 DOI: 10.1097/meg.000000000000127]
- 144 **Chan SS**, Luben R, Olsen A, Tjønneland A, Kaaks R, Lindgren S, Grip O, Bergmann MM, Boeing H, Hallmans G, Karling P, Overvad K, Venø SK, van Schaik F, Bueno-de-Mesquita B, Oldenburg B, Khaw KT, Riboli E, Hart AR. Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. *Aliment Pharmacol Ther* 2014; **39**: 834-842 [PMID: 24611981 DOI: 10.1111/apt.12670]
- 145 **Iskandar H**, Greer JB, Schraut WH, Regueiro MD, Davis PL, Hartman DJ, Siegel CA, Herfarth HH, Williams ED, Schwartz MB. IBD LIVE case series-case 1: smoking, a controversial but effective treatment for ulcerative colitis. *Inflamm Bowel Dis* 2014; **20**: 1696-1701 [PMID: 25167214 DOI: 10.1007/s10620-014-3350-9]
- 146 **de Silva PS**, Luben R, Shrestha SS, Khaw KT, Hart AR. Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries. *Eur J Gastroenterol Hepatol* 2014; **26**: 11-18 [PMID: 24216567 DOI: 10.1097/01.MIB.0000436275.12131.4f]
- 147 **Yamamoto T**, Shiraki M, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition to suppress postoperative Crohn's disease recurrence: a five-year prospective cohort study. *Int J Colorectal Dis* 2013; **28**: 335-340 [PMID: 23014978 DOI: 10.1097/MEG.0b013e328365c372]
- 148 **John S**, Luben R, Shrestha SS, Welch A, Khaw KT, Hart AR. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. *Eur J Gastroenterol Hepatol* 2010; **22**: 602-606 [PMID: 20216220 DOI: 10.1097/MEG.0b013e3283352d05]
- 149 **Spooren CE**, Pierik MJ, Zeegers MP, Feskens EJ, Masclee AA, Jonkers DM. Review article: the association of diet with onset and relapse in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2013; **38**: 1172-1187 [PMID: 24118051 DOI: 10.1111/apt.12501]
- 150 **Richman E**, Rhodes JM. Review article: evidence-based dietary advice for patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2013; **38**: 1156-1171 [PMID: 24102340 DOI: 10.1111/apt.12500]
- 151 **Andersen V**, Olsen A, Carbonnel F, Tjønneland A, Vogel U. Diet and risk of inflammatory bowel disease. *Dig Liver Dis* 2012; **44**: 185-194 [PMID: 22055893 DOI: 10.1016/j.dld.2011.10.001]
- 152 **Hou JK**, Lee D, Lewis J. Diet and inflammatory bowel disease: review of patient-targeted recommendations. *Clin Gastroenterol Hepatol* 2014; **12**: 1592-1600 [PMID: 24107394 DOI: 10.1016/j.cgh.2013.09.063]
- 153 **Charlebois A**, Rosenfeld G, Bressler B. The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review. *Crit Rev Food Sci Nutr* 2015; Epub ahead of print [PMID: 25569442 DOI: 10.1080/10408398.2012.760515]
- 154 **Flint HJ**, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 577-589 [PMID: 22945443 DOI: 10.1038/nrgastro.2012.156]
- 155 **Walker AW**, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J* 2011; **5**: 220-230 [PMID: 20686513 DOI: 10.1038/ismej.2010.118]
- 156 **Abraham C**, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. *Gastroenterology* 2011; **140**: 1729-1737 [PMID: 21530739 DOI: 10.1053/j.gastro.2011.02.012]
- 157 **Devkota S**, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB. Dietary-fat-

- induced taurocholic acid promotes pathobiont expansion and colitis in *Il10^{-/-}* mice. *Nature* 2012; **487**: 104-108 [PMID: 22722865 DOI: 10.1038/nature11225]
- 158 **Andersen V**, Holst R, Kopp TI, Tjønneland A, Vogel U. Interactions between diet, lifestyle and IL10, IL1B, and PTGS2/COX-2 gene polymorphisms in relation to risk of colorectal cancer in a prospective Danish case-cohort study. *PLoS One* 2013; **8**: e78366 [PMID: 24194923 DOI: 10.1371/journal.pone.0078366]
- 159 **Arthur JC**, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 2012; **338**: 120-123 [PMID: 22903521 DOI: 10.1126/science.1224820]
- 160 **Tjalsma H**, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. *Nat Rev Microbiol* 2012; **10**: 575-582 [PMID: 22728587 DOI: 10.1038/nrgastro.2012.172]
- 161 **Zintzaras E**. Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease? *Inflamm Bowel Dis* 2012; **18**: 562-572 [PMID: 21887726 DOI: 10.1038/nrmicro2819]
- 162 **Manichanh C**, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* 2006; **55**: 205-211 [PMID: 16188921 DOI: 10.1136/gut.2005.073817]
- 163 **Goldsmith JR**, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. *J Gastroenterol* 2014; **49**: 785-798 [PMID: 24652102 DOI: 10.1007/s00535-014-0953-z]
- 164 **Woodahl EL**, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. *Curr Drug Metab* 2004; **5**: 11-19 [PMID: 14965248 DOI: 10.2174/1389200043489108]
- 165 **Goldstein DB**, Hirschhorn JN. In genetic control of disease, does 'race' matter? *Nat Genet* 2004; **36**: 1243-1244 [PMID: 15565101 DOI: 10.1038/ng1204-1243]
- 166 **Andersen V**, Holst R, Vogel U. Systematic review: diet-gene interactions and the risk of colorectal cancer. *Aliment Pharmacol Ther* 2013; **37**: 383-391 [PMID: 23216531 DOI: 10.1111/apt.12180]
- 167 **Lewander A**, Butchi AK, Gao J, He LJ, Lindblom A, Arbmán G, Carstensen J, Zhang ZY, Sun XF. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. *Scand J Gastroenterol* 2007; **42**: 1332-1338 [PMID: 17852842 DOI: 10.1080/000365520701396026]
- 168 World Resources Institute Earth Trends The environmental information portal. 2009. Available from: URL: http://earthtrends.wri.org/searchable_db/index.php?theme=8&variable_ID=193&action=select_countries
- 169 **Kang CS**, Ban M, Choi EJ, Moon HG, Jeon JS, Kim DK, Park SK, Jeon SG, Roh TY, Myung SJ, Gho YS, Kim JG, Kim YK. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. *PLoS One* 2013; **8**: e76520 [PMID: 24204633 DOI: 10.1371/journal.pone.0076520]
- 170 **Bufe B**, Schumann T, Kappl R, Bogeski I, Kummerow C, Podgórska M, Smola S, Hoth M, Zufall F. Recognition of bacterial signal peptides by mammalian formyl peptide receptors: a new mechanism for sensing pathogens. *J Biol Chem* 2015; **290**: 7369-7387 [PMID: 25605714 DOI: 10.1074/jbc.M114.626747]
- 171 **Arpaia N**, Campbell C, Fan X, Dikly S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffey PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013; **504**: 451-455 [PMID: 24226773 DOI: 10.1038/nature12726]
- 172 **Jocelyn J**, Kasper LH. Digesting the emerging role for the gut microbiome in central nervous system demyelination. *Mult Scler* 2014; **20**: 1553-1559 [PMID: 25070675 DOI: 10.1177/1352458514541579]
- 173 **Kriegel MA**, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. *Proc Natl Acad Sci USA* 2011; **108**: 11548-11553 [PMID: 21709219 DOI: 10.1073/pnas.1108924108]
- 174 **Wu HJ**, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* 2010; **32**: 815-827 [PMID: 20620945 DOI: 10.1016/j.immuni.2010.06.001]
- 175 **Lee YK**, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci USA* 2011; **108** Suppl 1: 4615-4622 [PMID: 20660719 DOI: 10.1073/pnas.1000082107]
- 176 **Ivanov II**, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* 2009; **139**: 485-498 [PMID: 19836068 DOI: 10.1016/j.cell.2009.09.033]
- 177 **Yamada H**, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, Kaibara N, Hori A, Iwamoto Y, Yoshikai Y. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. *Ann Rheum Dis* 2008; **67**: 1299-1304 [PMID: 18063670 DOI: 10.1136/ard.2007.080341]
- 178 **Sarkar S**, Fox DA. Targeting IL-17 and Th17 cells in rheumatoid arthritis. *Rheum Dis Clin North Am* 2010; **36**: 345-366 [PMID: 20510238 DOI: 10.1016/j.rdc.2010.02.006]
- 179 **Kemppinen AK**, Kaprio J, Palotie A, Saarela J. Systematic review of genome-wide expression studies in multiple sclerosis. *BMJ Open* 2011; **1**: e000053 [PMID: 22021740 DOI: 10.1136/bmjopen-2011-000053]
- 180 **Shen W**, Durum SK. Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. *Neurochem Res* 2010; **35**: 940-946 [PMID: 19915978 DOI: 10.1007/s11064-009-0091-9]
- 181 **Baumgart DC**, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet* 2007; **369**: 1641-1657 [PMID: 17499606 DOI: 10.1016/S0140-6736(07)60751-X]
- 182 **Huebner C**, Browning BL, Petermann I, Han DY, Philpott M, Barclay M, Geary R, McCulloch A, Demmers P, Ferguson LR. Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. *Inflamm Bowel Dis* 2009; **15**: 1784-1793 [PMID: 19685447 DOI: 10.1677/joe.0.1780339]
- 183 **Farrell RJ**, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. *Gastroenterology* 2000; **118**: 279-288 [PMID: 10648456 DOI: 10.1016/S0016-5085(00)70210-1]
- 184 **Hirano T**, Onda K, Toma T, Miyaoka M, Moriyasu F, Oka K. MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration. *J Clin Pharmacol* 2004; **44**: 481-486 [PMID: 15102868 DOI: 10.1177/0091270004264162]

P- Reviewer: Aytac E, Ciccone MM **S- Editor:** Yu J **L- Editor:** A
E- Editor: Ma S





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgooffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>



ISSN 1007-9327

